GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Moberg Pharma AB (OTCPK:MBGPF) » Definitions » Loans Receivable

MBGPF (Moberg Pharma AB) Loans Receivable : $0.00 Mil (As of Sep. 2024)


View and export this data going back to 2015. Start your Free Trial

What is Moberg Pharma AB Loans Receivable?

Moberg Pharma AB's Loans Receivable for the quarter that ended in Sep. 2024 was $0.00 Mil.


Moberg Pharma AB Loans Receivable Historical Data

The historical data trend for Moberg Pharma AB's Loans Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Moberg Pharma AB Loans Receivable Chart

Moberg Pharma AB Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec20 Dec21 Dec22 Dec23
Loans Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Moberg Pharma AB Quarterly Data
Sep19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Loans Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Moberg Pharma AB Loans Receivable Calculation

Loans Receivable are the funds that a company has lent but have not yet been repaid.


Moberg Pharma AB Loans Receivable Related Terms

Thank you for viewing the detailed overview of Moberg Pharma AB's Loans Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Moberg Pharma AB Business Description

Traded in Other Exchanges
Address
Gustavslundsvagen 42, 5th Floor, Bromma, Stockholm, SWE, SE-167 51
Moberg Pharma AB is a Swedish pharmaceutical company focused on commercializing proprietary innovations based on drug delivery of compounds. The company develops and markets consumer healthcare products that relieve pain and treat skin conditions, mainly nail fungus. The Company's main product, MOB-015, is a novel topical treatment for onychomycosis It has a single operating segment, the development, and commercialization of medical products. Its geographic areas are Europe, the Americas, and Rest of the world.